AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01383811 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Intensity Aerobic Exercise
Description: Individuals in this group will receive moderate intensity exercise in addition to their usual care (Medications+/-Psychotherapy). The moderate intensity exercise program will involve gradual progression in exercise intensity and duration. During the first 4 weeks, participants will attend 3 supervised sessions/week and will be asked to complete at least 2 unsupervised aerobic exercise sessions/week. From weeks 5-8 the number of supervised sessions will be 2/week with at least 3 unsupervised aerobic exercise sessions/week. From weeks 9-12, the participants will have only 1 supervised session/week and will be asked to complete at least 4 unsupervised aerobic exercise sessions/week. In total, the participants will be required to complete 150 minutes of moderate physical activity/week.
Study NCT01383811 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wait-list
Description: The wait list/usual care group will continue with their usual standard treatment (Medications +/- Psychotherapy) as before.
Study NCT01383811 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Wait-list
Description: The wait list/usual care group will continue with their usual standard treatment (Medications +/- Psychotherapy) as before.
Study NCT04040049 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: FLT190
Description: Gene Therapy product.
Study NCT03445533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Arm A: 4 doses administered intravenously at a dose of 3 mg/kg over 90 minutes on Weeks 1, 4, 7, and 10.
Study NCT03445533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tilsotolimod with Ipilimumab
Description: IMO-2125 intratumoral injection administered as 9 doses on Weeks 1, 2, 3, 5, 8, 11, 16, 20, and 24. WITH (Arm B): Ipilimumab administered as 4 doses on Weeks 2, 5, 8, and 11. in combination with tilsotolimod
Study NCT00174447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: Dosage may subsequently be adjusted according to clinical status, only at each protocol visit and step by step between 40, 60 and 80 mg bid
Study NCT03560570 — intervention group
Intervention type: BIOLOGICAL
Intervention: Coagulation assay
Description: Conventional coagulation assays: prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, factor II, FV, FVII, FX, FVIII, FIX, FXI, FXII, d-dimers, antithrombin, protein C, protein S Thrombin generation assay: in presence or not of soluble thrombomodulin
Study NCT03560570 — intervention group
Intervention type: OTHER
Intervention: Clinical data collection
Description: At inclusion, we recorded clinical data about the disease (type and form of congenital disorder of glycosylation, and antecedent of microvascular event: thrombosis, stroke-like or hemorrhages)
Study NCT02296749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Sirolimus tablets 2 mg
Study NCT02296749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus tablets 2 mg
Study NCT00226915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel+Carboplatin
Description: Paclitaxel 180mg/m2＋CBDCA AUC6 q21 days x 6-9cycles
Study NCT00226915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel+Carboplatin
Description: Paclitaxel 80mg/m2 weekly ＋CBDCA AUC6 q21 days x 6-9cycles
Study NCT02148510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monobloc
Description: Construction fitted to upper and lower jaw
Study NCT02148510 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bibloc
Description: Biblock construction
Study NCT03293836 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: Radiofrequency ablation of insufficient saphenous and perforating veins using Closure Fast and Closure Stylet catheters (medtronic)
Study NCT03293836 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multilayer Compressive Bandage
Description: Individual receive multilayer compressive bandage once a week
Study NCT03293836 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multilayer Compressive Bandage
Description: Individual receive multilayer compressive bandage once a week
Study NCT01192789 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Amoxicillin
Description: LHWs treat severe pneumonia with oral amoxicillin at 90 mg/kg/day.
Study NCT01192789 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Referral to Health facility
Description: LHWs refer the severe pneumonia case to local health facility or private practitioner. In case of refused referral , treat the case with oral cotrimoxazole for 7 days.
Study NCT01579643 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OCT guided laser-assisted lamellar anterior keratoplasty (LALAK)
Description: 1. The top hat-shaped donor cornea graft with tapered brim will be cut using a femtosecond (fs) laser at the eye bank. An anterior diameter of 6.0 mm will be used. The depth of the anterior side cut will match the planned excimer ablation depth.~2. The host cornea bed will be prepared with an excimer laser.~3. Descemet's membrane will be peeled off the graft, and the graft sutured into the host bed.
Study NCT01579643 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Penetrating Keratoplasty (KP)
Description: 1. A trephine is used to perform a full thickness cut of a round area of cornea from the both patient's and donor's cornea.~2. The donor cornea is then sutured where the patient's cornea was.
Study NCT04176289 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: PPI measurement
Description: The pupillary dilatation reflex (PDR), induced by a standardized noxious stimulus will be measured as Pupillary Pain Index(PPI,11-point numeric scale, 0= no pain, 10= worst pain) determined with a portable pupillometer. Patients experiencing mild or more severe pain (PPI> 3) will receive intravenous opioid titration (piritramid, 3 mg bolus steps) and PPI measurement performed before and after intravenous opioid titration.
Study NCT02389322 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5μg/ml ESAT6-CFP10
Description: The participants are injection intradermally with 0.1 ml 5μg/ml ESAT6-CFP10 12 weeks after BCG immunization or placebo immunization.This biological diagnostic reagents is injection agent .Every subject apply for the 5μg/mlRecombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 only one time after choosing into study population II .
Study NCT02389322 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10μg/ml ESAT6-CFP10
Description: The participants are injection intradermally with 0.1 ml 10μg/ml ESAT6-CFP10 12 weeks after BCG immunization or placebo immunization.This biological diagnostic reagents is injection agent .Every subject apply for the 10μg/mlRecombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 only one time after choosing into study population II .
Study NCT02389322 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: The participants are injected intradermally with 0.1 ml BCG.This BCG is Freeze-dried agent and with five people dose of each bottle,so each bottle of BCG must dissolve by 0.5ml special diluent before administration.Every subject apply for the BCG vaccine only one time after choosing into study population II .
Study NCT02389322 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The participants are injected intradermally with 0.1 ml placebo of Bacillus Calmette-Guerin.This placebo is Freeze-dried agent and with five people dose of each bottle ,so each bottle must dissolve by 0.5ml special diluent before administration.Every subject apply for the BCG vaccine only one time after choosing into study population II .
Study NCT03936842 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breast Pain video
Description: An educational video of approximately 10 minutes about breast pain, self-examination and breast awareness will be shown to the participant.
Study NCT03936842 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Semi-structure interviews
Description: A semi-structured, face-to-face interview will be then undertaken. The principles of Grounded Theory will be used to guide the interview. All of the interviews will be recorded and transcribed securely, only referencing the patient according to their study number. Their name and hospital number will not be used.
Study NCT04513743 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 24/7 EEG™ SubQ
Description: 24/7 EEG™ SubQ device will be worn by each subject for 365 nights
Study NCT06147492 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: transanal total mesorectal excision
Description: a transanal bottom-up approach was employed for the TME procedure
Study NCT06147492 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic Total Mesorectal Excision
Description: Laparoscopic Total Mesorectal Excision
Study NCT04264546 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sIPV
Description: The investigational High dosage Sabin IPV was all developed by Minhai Biotech Co., LTD. The antigen contents of type I, type II and type III polioviruses in the high dosage Sabin IPV were 22 DU, 65 DU and 65 DU. The vaccine was in liquid form, 0.5 ml per dose.
Study NCT00777998 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Auto-Allo Tandem SCT and maintenance therapy with Thalidomide/ DLI
Description: \*Multiple myeloma~* -> Induction Therapy (max. 8 cycles)~* -> Registration of patient, stem cell mobilization, start of donor search~* -> Melphalan (200mg/qm) plus autologous PBSCT~* -> 2 months later: Melphalan plus allogeneic PBSCT~* -> day 120 after allogeneic PBSCT: Thalidomide, 100mg (max. 2 years or until progress or non-tolerable toxicity, respectively)~* -> day 180 after allogeneic PBSCT (if CsA discontinued): First DLI (1 x 10\^6 (MRD) or 5 x 10\^5 (MUD) CD3+ cells per kg BW)~* -> day 250 after allogeneic PBSCT: second DLI (if no signs of GvHD: dose escalation by 0,5 Log)~* -> Day 320 after allogeneic PBSCT: Third DLI (if no signs of GvHD: dose escalation by 0,5 Log)~* -> Further DLI depending on MRD-measurement
Study NCT00777998 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: auto-auto Tandem stem cell transplantation and maintenance therapy with Thalidomide
Description: \*Multiple myeloma~* -> Induction Therapy (max. 8 cycles)~* -> Registration of patient, stem cell mobilization, start of donor search~* -> Melphalan (200mg/qm) plus autologous PBSCT~* -> if no donor available (max 4 weeks after autologous PBSCT) or if patients declines allogeneic PBSCT): 2 months: Melphalan (200mg/qm) plus autologous PBSCT~* -> day 120 after autologous PBSCT: Thalidomide, 100mg (max. 2 years or until progress or non-tolerable toxicity, respectively)
Study NCT03084276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fat meal
Description: High-fat meal
Study NCT03084276 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-fat meal
Description: Low-fat meal with the same physical and organoleptic characteristics as the high-calorie meal.
Study NCT03469726 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Contrast-enhanced Diffusion-weighted MRI
Description: An MRI scan enhanced with intravenous contrast and with diffusion imaging at several B-values
Study NCT01851707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-145
Description: 2 blinded capsules will be administered twice a day (morning and night) for 12 weeks.
Study NCT01851707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 blinded capsules will be administered twice a day (morning and night) for 12 weeks.
Study NCT02412579 — intervention group
Intervention type: OTHER
Intervention: None - Standard of Care
Study NCT00479830 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: To collect data to assess the unmet health and cancer needs of the South Asian population in the Greater Houston area and to determine barriers and other factors that affect health in this population.
Study NCT00479830 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interview
Description: To collect data to assess the unmet health and cancer needs of the South Asian population in the Greater Houston area and to determine barriers and other factors that affect health in this population.
Study NCT03519919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: somofilcon A multifocal lens
Description: contact lens
Study NCT03910140 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TILA-TACE treatment
Description: TACE was performed through the transfemoral route using a 5-Fr catheter (Shepherd-hook modified Angiographic Catheter, HANACO Medical, Tian Jin, China ) that was advanced from celiac artery to common hepatic artery, proper hepatic artery, hepatic artery and ultimately to tumor feeding arteries which are defined by angiography. Then, a coaxial microcatheter (2.8 Fr Marguerite II, ASAHI INTECC GMA CO., LTD, Nagoya, Japan) was selectively inserted through a 5-Fr catheter into the tumor feeding artery, into which, 5% sodium bicarbonate was infused alternatively with doxorubicin-lipiodol emulsion. Finally, the artery was embolized with PVA (Embosphere®, BioSphere Medical, Paris, France) and microcoil ( Tornado ®, COOK Medical, USA).
Study NCT03578445 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-guided microbiopsy
Description: Use of EUS-guided through-the-needle microbiopsy forceps for obtainment of tissue from the wall of the cystic lesion
Study NCT03578445 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Next Generation Sequencing
Description: Prevalence of genetic mutations in known cancer-associated genes in the microbiopsy tissue examined using the Ion AmpliSeq Cancer Hotspot Panel v2 (Life Technologies, Carlsbad, USA). The multigene panel explores selected regions of 50 cancer-associated genes, among others KRAS, GNAS, CDKN2A and SMAD4 genes.
Study NCT02333994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GROUP A education programme as well as balance training exercises
Description: Group A received education programme as well as balance training exercises.The intervention group attended one-hour training classes once a week for 6 consecutive weeks. The classes involved both lectures and discussions and were guided through with handouts and worksheets. Each session began by giving a summary of the previous session and continued with the main topic of the session. The intervention program also engaged the participants in discussions about their concerns regarding falling and on topics pertaining to identifying and reducing the risk factors of falls, including environmental hazards in and out of the house
Study NCT02333994 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GROUP B on-platform training
Description: on-platform training was performed while standing and while sitting on a 22-inch therapeutic ball, 1 eyes open or closed 2 normal or reduced area of foot support 3 on foam or floor 4 with or without manual p
Study NCT00255840 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring by an HIV-trained medical doctor
Description: Participants will receive care from an HIV-trained medical doctor
Study NCT00255840 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring by an HIV-trained primary care nurse
Description: Participants will receive care from an HIV-trained primary care nurse
Study NCT00255840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: 600 mg tablet taken orally daily
Study NCT00255840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: 150 mg tablet taken orally daily
Study NCT00255840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir
Description: 400 mg lopinavir/100mg ritonavir tablet taken orally twice daily
Study NCT00255840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine
Description: 200 mg tablet taken orally for 14 days before taking a 200 mg tablet orally twice daily
Study NCT00255840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stavudine
Description: Tablet taken orally daily. Dosage depends on weight.
Study NCT04365673 — intervention group
Intervention type: OTHER
Intervention: Pharmacist transition of care consultation
Description: Pharmacist-delivered comprehensive medication review
Study NCT04361760 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: single-puls TMS
Description: Medical Device (MD): MagPro X100
Study NCT04361760 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham stimulation
Description: Sham stimulation is delivered with a dedicated coil, which is magnetically shielded and thus produces only approx. 20% of the nominal magnetic field. This is not enough to reach and stimulate the cortex, but the produced sound and scalp sensation are the same as with a real TMS coil.
Study NCT04401202 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nigella sativa oil
Description: Nigella sativa oil 500mg softgel capsules in oral twice daily dose for 10 days
Study NCT02671617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT)
Description: Preoperative HIIT protocol.
Study NCT00561535 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus FARCIMINIS
Description: 10.10 UFC of lactobacillus FARCIMINIS
Study NCT00561535 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo (starch)
Description: Once daily
Study NCT01838772 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pegylated-Interferon and Ribavirin
Description: This is an open-label, single arm demonstration study. Intervention consists in treatment with Pegylated-interferon (Peg-Intron®, 1.5 microgr/kg/week, as subcutaneous injection) and ribavirin (Rebetol®, weight-based dosing, 2-daily doses) for 48 weeks, or 24 weeks for patients with genotype 2 and 3, moderate liver fibrosis, and rapid virological response.
Study NCT04053244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: internet-based cognitive behavioural therapy
Description: Designed for general clinical use (but not specifically cardiac patients), it consists of 5 online modules outlining cognitive-behavioural skills for depression, completed over 7-8 weeks. The participants will be guided step-wise through the modules by the therapist. Participants can work more or less at their own pace, but are expected to proceed to the next module within 1-2 weeks. Because the content is identical for each participant, fidelity to the web-based component of the intervention is ensured.
Study NCT00966732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga of Awareness Program
Description: The 8 week yoga program will meet in groups of about 8-10 persons. Each 2-hour session will include gentle stretching, strengthening, and balance poses; meditation exercises; breathing techniques; study of pertinent topics (eg, mind/body stress reactivity), and group discussions (eg, experiences while practicing yoga). Participants will be asked to practice yoga methods at home, guided by a DVD (or audio recordings). The program will be taught by a certified yoga teacher (RYT) who has extensive experience in teaching yoga to medical patients.
Study NCT03825822 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ImPaC Resource Intervention (INT)
Description: A Change Team will lead the implementation process of the ImPaC Resource using the steps:~Step 1: Complete a checklist to ensure its members can commit to responsibilities.~Step 2: Reflect on the unit's readiness for change.~Step 3: Perform an audit on 10 to 15 medical charts.~Step 4: Identify a practice change based on audit results (pain assessment or pain treatment). Develop an aim statement for the practice change.~Step 5: Select the KT strategies and plan the implementation.~Step 6: Perform an audit on 10 to 15 medical charts.~Step 7: Examine the effectiveness of the implementation and decide on the aim and KT strategies for the next cycle of change.
Study NCT03825822 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Practice (SP)
Description: The SP arm will continue as usual with their standard pain practices and will be offered the intervention 6 months after randomization and completion of data collection.
Study NCT02710552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tripliam (perindopril, indapamide, amlodipine)
Description: Fixed combination of perindopril 5 mg, indapamide 1,25 and amlodipine 5 mg
Study NCT02710552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reaptan (perindopril, amlodipine)
Description: Fixed combination of perindopril 10 mg and amlodipine 5 mg
Study NCT00560482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABR-215050, tasquinimod
Description: Gelatin capsules containing 0.25mg, 0.50mg, 1.0mg ABR-215050; 0.25mg/day taken orally once daily for 2 weeks, 0.50mg/day taken orally once daily for 2 weeks (dose-titration), and 1.0 mg/day taken once daily for 5 months (+6 months continuation)
Study NCT00560482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical appearing gelatin capsules containing placebo
Study NCT02139774 — intervention group
Intervention type: BEHAVIORAL
Intervention: Walk with Ease
Description: A six week walking program by the Arthritis Foundation
Study NCT00520845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: 600 mg will be taken by mouth twice a day for 6 weeks then 400 mg twice a day for up to a year after chemotherapy is discontinued in the absence of progression.
Study NCT00520845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m2 given through a vein over 90 minutes on day 1 of a 3-week cycle